EDP 322
Alternative Names: EDP-322Latest Information Update: 16 Jul 2016
At a glance
- Originator Enanta Pharmaceuticals
- Class Antibacterials; Macrolides; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections(In volunteers) in USA (PO)
- 15 Sep 2008 Phase-I clinical trials in Bacterial infections in USA (PO)